Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia

Data presented at the 2018 American Society of Hematology Annual Meeting showed that although some patients with Waldenstrom macroglobulinemia (WM) necessitate dose reductions with ibrutinib due to toxicities such as cytopenias, arrhythmia, and musculoskeletal discomfort, it doesn’t seem to affect progression-free survival. Among 217 patients initiated on 420 mg ibrutinib once per day, 27% required a dose reduction at a median follow-up of over 2 years, and there was no significant difference in those patients’ PFS compared with patients who did not have a dose reduction.

Blood (ASH Abstract)